Literature DB >> 32065323

Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro.

Alexandria Turner1, Danielle R Bond2,3, Quan V Vuong2, Anita Chalmers2, Emma L Beckett2,3, Judith Weidenhofer3,4, Christopher J Scarlett2.   

Abstract

Treatment options for pancreatic cancer (PC) are severely limited due to late diagnosis, early metastasis and the inadequacy of chemotherapy and radiotherapy to combat the aggressive biology of the disease. In recent years, plant-derived bioactive compounds have emerged as a source of novel, anti-cancer agents. Used in traditional medicine worldwide, Elaeocarpus species have reported anti-inflammatory, antioxidant and anti-cancer properties. This study aimed to isolate and identify potential anti-PC compounds in the fruit of Elaeocarpus reticulatus Sm. A 50% acetone crude extract significantly decreased the viability of four pancreatic cell lines (≥ 10 µg/mL for BxPC-3 cells) and induced apoptosis in BxPC-3 and HPDE cells. Analysis by HPLC identified the triterpenoid Cucurbitacin I as a likely component of the extract. Furthermore, treatment with Cucurbitacin I significantly reduced the viability of HPDE and BxPC-3 cells, with results comparable to the same concentration of gemcitabine. Interestingly, attempts to isolate bioactive compounds revealed that the crude extract was more effective at reducing PC-cell viability than the fractionated extracts. This study provides initial insight into the bioactive constituents of E. reticulatus fruits.

Entities:  

Keywords:  Apoptosis; Cucurbitacin I; Elaeocarpus reticulatus; Pancreatic cancer

Mesh:

Substances:

Year:  2020        PMID: 32065323     DOI: 10.1007/s11033-020-05307-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  54 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Calcium sensing receptor suppresses human pancreatic tumorigenesis through a novel NCX1/Ca(2+)/β-catenin signaling pathway.

Authors:  Bo Tang; Jimmy Y C Chow; Tobias Xiao Dong; Shi-Ming Yang; De-Sheng Lu; John M Carethers; Hui Dong
Journal:  Cancer Lett       Date:  2016-04-20       Impact factor: 8.679

Review 3.  Pancreatic cancer stem cells: emerging target for designing novel therapy.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2012-03-20       Impact factor: 8.679

Review 4.  Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter?

Authors:  Caroline Verbeke
Journal:  Pancreatology       Date:  2016-02-17       Impact factor: 3.996

Review 5.  Biology and clinical applications of pancreatic cancer stem cells.

Authors:  Ethan V Abel; Diane M Simeone
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 6.  A starring role for stellate cells in the pancreatic cancer microenvironment.

Authors:  Minoti V Apte; Jeremy S Wilson; Aurelia Lugea; Stephen J Pandol
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

7.  Tumor heterogeneity confounds and illuminates: assessing the implications.

Authors:  Maria Kleppe; Ross L Levine
Journal:  Nat Med       Date:  2014-04       Impact factor: 53.440

8.  Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.

Authors:  Daisuke Hashimoto; Kota Arima; Naomi Yokoyama; Akira Chikamoto; Katsunobu Taki; Risa Inoue; Takayoshi Kaida; Takaaki Higashi; Hidetoshi Nitta; Masaki Ohmuraya; Masahiko Hirota; Toru Beppu; Hideo Baba
Journal:  Pancreas       Date:  2016-09       Impact factor: 3.327

Review 9.  Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.

Authors:  Prashanth Rawla; Tagore Sunkara; Vinaya Gaduputi
Journal:  World J Oncol       Date:  2019-02-26

Review 10.  Epidemiology of pancreatic cancer.

Authors:  Milena Ilic; Irena Ilic
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.